Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT	OF CHANGE	S IN BENEFICIAL	OWNERSHIP

OMB APPROVAL										
OMB Number: 3235-028										
Estimated average burden										
hours per response	9: 0.5									

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Could Deboat I					2. Issuer Name and Ticker or Trading Symbol Fulcrum Therapeutics, Inc. [FULC]								Relationship of Reporting Person(s) to Issuer (Check all applicable)						
Gould Robert J						Zaciam Inclupedates, inc. [1020]							:	X Direc	tor		10% O	wner	
(Last)	(F	irst) (1	Middle)		3. Da	Date of Earliest Transaction (Month/Day/Year)									X Officer (give title below)			Other (below)	specify
C/O FULCRUM THERAPEUTICS, INC.					06/0	06/09/2020							See Remarks						
26 LANDSDOWNE STREET																			
					4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable						
(Street)														Line	,	filed by On	a Dans	autina Dava	
CAMBR	IDGE M	IA 0	2139											-	_	filed by On		J	
															Form filed by More than One Reporting Person				
(City)	(5	tate) (2	Zip)																
		Table	I - Nor	n-Deriva	tive S	Secu	rities	Acq	uired,	Dis	oosed of	, or E	3ene	ficia	lly Own	ed			
1. Title of Security (Instr. 3) 2. Transac Date (Month/Da			Execution Date,				es Acquired (A) o Of (D) (Instr. 3, 4			Benefic Owned	ties cially Following	Form (D) or	: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership					
									Code	v	Amount	Amount (A) or (D)		Price	Transa	Reported Transaction(s) (Instr. 3 and 4)			(Instr. 4)
Common Stock 06/09/3				′2020			S ⁽¹⁾		156)	\$20	539,845			D			
		Tal									sed of,				y Owne	d			
				(e.g., pu	its, ca	alis, v	warra	ants,	optior	ıs, c	onvertib	le se	curit	ies)					1
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		if any	med on Date, Day/Year)		Transaction of Code (Instr. Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Insi 3 and 4)			3. Price of Derivative Security (Instr. 5)	tive derivative ty Securities		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exercisa	able	Expiration Date	Title	Amo or Num of Shar	ber					

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2019.

Remarks:

President & Chief Executive Officer

/s/ Peter Thomson, as 06/10/2020 attorney-in-fact for Robert J. Gould

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.